Drug Profile
Research programme: stem cell therapies - Stemedica Cell Technologies
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Stemedica Cell Technologies
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain injuries; Unspecified; Wounds
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Undefined in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Wounds in USA (Parenteral)